One pill is the difference between staying on treatment and drifting away
No Brasil, onde mais de 400 mil pacientes convivem com o HIV pelo sistema público de saúde, a Anvisa aprovou o Dovato — um comprimido diário único que reúne dois antivirais antes administrados separadamente. Desenvolvido pela ViiV Healthcare, subsidiária da GSK, o medicamento representa não apenas um avanço farmacológico, mas uma resposta à realidade humana de que a adesão ao tratamento é, em si mesma, uma forma de cura. Simplificar é, às vezes, o gesto mais profundo que a medicina pode oferecer.
- Tomar vários comprimidos por dia pode parecer rotina, mas para quem vive com HIV, cada dose esquecida é uma brecha que o vírus pode explorar — e o Dovato nasce justamente para fechar essa brecha.
- A combinação de lamivudina e dolutegravir em um único comprimido desafia o padrão do mercado, onde a maioria dos tratamentos de dose única ainda exige três ou mais fármacos.
- O mecanismo duplo do medicamento ataca o vírus em duas frentes distintas: impede que o HIV integre seu DNA às células humanas e bloqueia a replicação viral, permitindo que as células CD4 se recuperem.
- A aprovação vale para adultos e adolescentes acima de 12 anos e pode ser usada tanto como tratamento inicial quanto como substituição para quem já tem a carga viral suprimida.
- Com dolutegravir já presente no sistema público desde 2016 e meio milhão de brasileiros dependendo dele, a chegada do Dovato amplia as opções clínicas sem abandonar o que já funciona.
A Anvisa aprovou o Dovato, medicamento desenvolvido pela ViiV Healthcare — subsidiária da GSK — que combina dois antivirais, lamivudina e dolutegravir sódico, em um único comprimido de uso diário. A novidade pode parecer discreta, mas carrega um peso prático considerável: no tratamento do HIV, aderir à medicação de forma contínua é tão importante quanto a eficácia do próprio fármaco. Reduzir o número de comprimidos é, portanto, uma estratégia clínica, não apenas uma conveniência.
O que distingue o Dovato dos demais tratamentos de dose única disponíveis no Brasil é que ele alcança eficácia comparável à de regimes com três ou quatro medicamentos usando apenas dois. O dolutegravir impede que o vírus integre seu DNA ao material genético das células humanas, enquanto a lamivudina bloqueia a conversão do RNA viral em DNA, interrompendo a replicação. Juntos, suprimem o HIV a níveis baixos e permitem a recuperação das células CD4, essenciais para a imunidade. Segundo a GSK, o resultado é menor toxicidade e menor risco de resistência viral.
O medicamento é indicado para adultos e adolescentes com mais de 12 anos e pelo menos 40 quilogramas, podendo ser usado tanto por quem inicia o tratamento quanto por quem já tem carga viral controlada e deseja simplificar sua rotina terapêutica. O contexto brasileiro torna a aprovação ainda mais relevante: o dolutegravir já é amplamente distribuído pelo SUS desde 2016, e mais de 400 mil pacientes o utilizam — cerca de metade de todos os que recebem tratamento antirretroviral pelo sistema público. Para essa população, a possibilidade de consolidar a medicação em um único comprimido pode significar mais qualidade de vida e maior continuidade no cuidado.
Brazil's health regulator has approved a new HIV medication that does something simple but significant: it puts two different antiviral drugs into a single daily pill. The drug is called Dovato, developed by ViiV Healthcare, a subsidiary of the British pharmaceutical company GSK. The approval matters because it represents a shift in how HIV treatment works in practice—fewer pills to take each day means patients are more likely to stick with their regimen, and adherence is everything in managing a chronic viral infection.
The two antivirals combined in Dovato are lamivudina and dolutegravir sódico. What makes this pairing notable is that until now, these two drugs were not available together in a single tablet in Brazil. Most single-pill HIV treatments on the market contain at least three different medications. Dovato achieves comparable effectiveness with just two, which GSK says reduces the medication burden while maintaining both efficacy and what's called a high barrier to resistance—meaning the virus is less likely to develop immunity to the treatment.
The mechanics are straightforward. Dolutegravir works by blocking the virus's ability to integrate its DNA into human cells. Lamivudina takes a different approach, interfering with the conversion of viral RNA into DNA, which prevents the AIDS virus from replicating in the body. Together, they suppress HIV to low levels, which allows CD4 cells—a type of white blood cell crucial to immune function—to recover and rebuild the body's defenses against infection. Rafael Maciel, a medical manager at GSK, notes that the formula achieves "maintenance of efficacy with lower medication use and lower potential for toxicity," which translates to fewer side effects and a simpler daily routine.
The approval applies to adults and adolescents over 12 years old who weigh at least 40 kilograms. Patients can use it either as a first-line treatment or as a replacement for their current antiviral regimen, provided their viral load is already suppressed. This flexibility matters because it means the drug can help people who are already managing their infection but want to simplify their treatment schedule.
Context matters here. Dolutegravir was added to Brazil's public health system in 2016, and it has since become widely used—more than 400,000 Brazilian patients currently take it through the public system, representing roughly half of all people receiving HIV treatment through government health services. That's a substantial population, and for them, the option to consolidate their daily medications into a single pill could meaningfully improve their quality of life and their likelihood of staying on treatment long-term. The approval expands the toolkit available to physicians treating HIV in Brazil, giving them another option to match to individual patient needs and circumstances.
Notable Quotes
The approval represents an advance in treating people with the virus that causes AIDS, since it brings together in one daily dose two antiretrovirals that were not available in a single pill— Anvisa
Dovato provides significant results with just two medications in one pill, demonstrating through studies to be equally as effective as HIV treatments with three or four medications— Rafael Maciel, medical manager at GSK/ViiV Healthcare
The Hearth Conversation Another angle on the story
Why does it matter that two drugs are in one pill instead of two separate ones?
Because people forget. Or they get tired. Or the side effects of managing multiple pills every single day wear them down. With HIV, missing doses isn't just inconvenient—it's how the virus learns to resist the drugs. One pill is the difference between someone staying on treatment and someone drifting away from it.
But couldn't someone just take two pills instead of one?
Technically yes. But in practice, no. Every additional pill is friction. It's another thing to remember, another thing to carry, another thing that signals to the world that you're managing a chronic illness. Simplicity is medicine too.
How does this compare to what was available before?
Most single-pill HIV treatments combine three or four different drugs. Dovato does the same job with two. That means less chemical load on the body, potentially fewer side effects, and still the same protective barrier against the virus developing resistance.
Who benefits most from this?
People starting treatment for the first time, and people already on treatment who want to simplify. In Brazil, that's potentially hundreds of thousands of people. But it's also anyone who's struggled with the daily ritual of multiple medications—which is most people, honestly.
Is there a catch?
It's not for everyone. You need to be over 12 and weigh at least 40 kilograms. And if you've never been treated before, or if your virus is already controlled, it works. But it's not a magic cure—it's a tool that makes living with HIV a little less complicated.